May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's VSTM.O combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.